Publication:
Effectiveness of 0.1% topical tacrolimus in adult and children patients with vitiligo

dc.contributor.authorUdompataikul M.
dc.contributor.authorBoonsupthip P.
dc.contributor.authorSiriwattanagate R.
dc.date.accessioned2021-04-05T03:35:21Z
dc.date.available2021-04-05T03:35:21Z
dc.date.issued2011
dc.date.issuedBE2554
dc.description.abstractTopical corticosteroids and phototherapy are the conventional treatments of vitiligo. However, the acrofacial and segmental types are often unresponsive to these treatments. Nowadays, a few studies have been conducted on efficacy of topical tacrolimus in treatment of vitiligo including vulgaris and segmental types. Nevertheless, the acrofacial type has never been investigated with this topical therapy. The aim of our study is to evaluate the effectiveness of 0.1% tacrolimus ointment in patients including all types of vitiligo. Forty-two patients with vitiligo (22 adults, 20 children) were enrolled in this study. They were treated with 0.1% tacrolimus ointment twice daily for 6 months. Of these 42 patients, 38 of them completed the treatment process. The mean age of the patients was 27.8 years. The response rate was 76.09%. The vulgaris and focalis had a maximum response rate of 94.12%. The response rates for segmentalis and acrofacialis were 76.92% and 56.25% respectively. Concerning the response, age groups, types and location of vitiligo, there was significant difference in all variables (P = 0.001, P = 0.001, P = 0.025, respectively). Children had approximately nine times higher odds (95% CI = 1.09, 81.88) of having better response to the treatment than adults. The disease duration of 5 years or less also showed a better response. In conclusion, topical tacrolimus can be used for the treatment of patients with vitiligo. We recommend that, other than in the vulgaris type, topical tacrolimus may be considered as a treatment for two difficult to treat types of vitiligo, acrofacialis and segmentalis, before considering other modalities. © 2010 Japanese Dermatological Association.
dc.format.mimetypeapplication/pdf
dc.identifier.citationJournal of Dermatology. Vol 38, No.6 (2011), p.536-540
dc.identifier.doi10.1111/j.1346-8138.2010.01067.x
dc.identifier.issn3852407
dc.identifier.other2-s2.0-79957909125
dc.identifier.urihttps://hdl.handle.net/20.500.14740/7323
dc.rights.holderมหาวิทยาลัยศรีนครินทรวิโรฒ
dc.subject.otherTacrolimus
dc.subject.otherAdult
dc.subject.otherArticle
dc.subject.otherBurning sensation
dc.subject.otherChild
dc.subject.otherClinical article
dc.subject.otherClinical trial
dc.subject.otherDisease duration
dc.subject.otherDrug efficacy
dc.subject.otherErythema
dc.subject.otherFemale
dc.subject.otherGroups by age
dc.subject.otherHuman
dc.subject.otherMale
dc.subject.otherTopical treatment
dc.subject.otherTreatment outcome
dc.subject.otherTreatment response
dc.subject.otherVitiligo
dc.subject.otherAdministration, Cutaneous
dc.subject.otherAdult
dc.subject.otherChild
dc.subject.otherFemale
dc.subject.otherHumans
dc.subject.otherImmunosuppressive Agents
dc.subject.otherMale
dc.subject.otherTacrolimus
dc.subject.otherTreatment Outcome
dc.subject.otherVitiligo
dc.titleEffectiveness of 0.1% topical tacrolimus in adult and children patients with vitiligo
dc.typeArticle
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-79957909125&doi=10.1111%2fj.1346-8138.2010.01067.x&partnerID=40&md5=a5b6f1cc352605e4f84c2ac5beaf3240

Files